Adma Biologics (ADMA) Depreciation & Amortization (CF) (2011 - 2025)

Adma Biologics has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 5.25% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.1 million (up 0.63% YoY), and the FY2025 full-year result was $8.1 million, up 0.63% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $2.0 million, up from $2.0 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.1 million in Q1 2024, with the low at $1.2 million in Q1 2021.
• Historically, Depreciation & Amortization (CF) has averaged $1.9 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 55.88% — and 2024, when it slipped 7.82%.
• Adma Biologics' Depreciation & Amortization (CF) stood at $1.5 million in 2021, then advanced by 27.55% to $1.9 million in 2022, then grew by 8.91% to $2.1 million in 2023, then slipped by 7.82% to $1.9 million in 2024, then increased by 5.25% to $2.0 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.